Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,236 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis.
Kawano Y, Kim K, Min CK, Koh Y, Ishizawa K, Kim SH, Ito S, Tanaka J, Uchiyama M, Ishida T, Kim JS, Moreau P, Martin T, Tada K, Risse ML, Suzuki K. Kawano Y, et al. Among authors: tada k. Clin Lymphoma Myeloma Leuk. 2023 Oct;23(10):e360-e367. doi: 10.1016/j.clml.2023.06.011. Epub 2023 Jul 3. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37479547 Free article. Clinical Trial.
Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis.
Sunami K, Ikeda T, Huang SY, Wang MC, Koh Y, Min CK, Yeh SP, Matsumoto M, Uchiyama M, Iyama S, Shimazaki C, Lee JH, Kim K, Kaneko H, Kim JS, Lin TL, Campana F, Tada K, Iida S, Suzuki K; ICARIA-MM study group. Sunami K, et al. Among authors: tada k. Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):e751-e761. doi: 10.1016/j.clml.2022.04.005. Epub 2022 Apr 8. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35641409 Free article.
Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study.
Ishida T, Ito S, Tanaka J, Uchiyama M, Kawano Y, Moreau P, Martin T, Risse ML, Tada K, Suzuki K, Ishizawa K. Ishida T, et al. Among authors: tada k. Jpn J Clin Oncol. 2022 Dec 5;52(12):1446-1449. doi: 10.1093/jjco/hyac137. Jpn J Clin Oncol. 2022. PMID: 36073950 Free PMC article. Clinical Trial. No abstract available.
Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study.
Sunami K, Suzuki K, Ri M, Matsumoto M, Shimazaki C, Asaoku H, Shibayama H, Ishizawa K, Takamatsu H, Ikeda T, Maruyama D, Kaneko H, Uchiyama M, Kiguchi T, Iyama S, Murakami H, Takahashi K, Tada K, Macé S, Guillemin-Paveau H, Iida S. Sunami K, et al. Among authors: tada k. Cancer Sci. 2020 Dec;111(12):4526-4539. doi: 10.1111/cas.14657. Epub 2020 Oct 15. Cancer Sci. 2020. PMID: 32975869 Free PMC article. Clinical Trial.
Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study.
Sunami K, Fuchida SI, Suzuki K, Ri M, Matsumoto M, Shimazaki C, Asaoku H, Shibayama H, Ishizawa K, Takamatsu H, Ikeda T, Maruyama D, Imada K, Uchiyama M, Kiguchi T, Iyama S, Murakami H, Onishi R, Tada K, Iida S. Sunami K, et al. Among authors: tada k. Hematol Oncol. 2023 Aug;41(3):442-452. doi: 10.1002/hon.3105. Epub 2022 Dec 15. Hematol Oncol. 2023. PMID: 36433829 Clinical Trial.
Clinical characteristics and results after conservative treatment or interfascicular neurolysis of 100 limbs with spontaneous anterior interosseous nerve palsy: A prospective Japanese multicenter study.
Ochi K, Tajiri Y, Kurimoto S, Kitamura Y, Tsuruta T, Ikegami S, Ikeda K, Satake H, Nishiwaki M, Hara Y, Kato N, Shinomiya R, Osada R, Tazaki K, Okazaki M, Omura T, Matsui Y, Yasunaga H, Amako M, Tanaka H, Kobayashi Y, Senma S, Nobuta S, Yamamoto S, Uchiyama S, Narisawa H, Tada K, Morisawa Y, Horiuchi Y, Kato H. Ochi K, et al. Among authors: tada k. J Orthop Sci. 2024 Nov 21:S0949-2658(24)00203-3. doi: 10.1016/j.jos.2024.10.009. Online ahead of print. J Orthop Sci. 2024. PMID: 39578131
Differences in the effects of exercise on blood pressure depending on the physical condition of the subject and the type of exercise: a systematic review and meta-analysis.
Suematsu Y, Morita H, Abe M, Uehara Y, Koyoshi R, Fujimi K, Ideishi A, Takata K, Kato Y, Hirata T, Yahiro E, Morito N, Kitajima K, Yano Y, Satoh A, Yoshimura C, Ishida S, Okutsu S, Takahashi K, Shinohara Y, Sakaguchi T, Katsuki S, Tada K, Fujii T, Funakoshi S, Hu Y, Satoh T, Ohnishi H, Okamura K, Mizuno H, Arakawa K, Asayama K, Ohtsubo T, Ishigami T, Shibata S, Fujita T, Munakata M, Ohishi M, Ichihara A, Katsuya T, Mukoyama M, Rakugi H, Node K, Arima H, Miura SI. Suematsu Y, et al. Among authors: tada k. Hypertens Res. 2024 Nov 1. doi: 10.1038/s41440-024-01974-3. Online ahead of print. Hypertens Res. 2024. PMID: 39487318
Current use of angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors for hypertension in patients with chronic kidney disease with proteinuria: a cross-sectional study based on real-world data.
Tada K, Nakano Y, Takahashi K, Hiyamuta H, Watanabe M, Ito K, Yasuno T, Abe M, Satoh A, Kawazoe M, Maeda T, Yoshimura C, Kosuke M, Arima H. Tada K, et al. Hypertens Res. 2024 Sep 19. doi: 10.1038/s41440-024-01896-0. Online ahead of print. Hypertens Res. 2024. PMID: 39300299
1,236 results